RARE (Ultragenyx Pharmaceutical) PB Ratio: (As of Jun. 25, 2026)


RARE Ultragenyx Pharmaceutical Inc RARE
65 GF Score
Price $29.25
GF Value $46.99
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Ultragenyx Pharmaceutical PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), Ultragenyx Pharmaceutical's share price is $29.25. Ultragenyx Pharmaceutical's Book Value per Share for the quarter that ended in Mar. 2026 was $-2.40. Hence, Ultragenyx Pharmaceutical's PB Ratio of today is .

The historical rank and industry rank for Ultragenyx Pharmaceutical's PB Ratio or its related term are showing as below:

During the past 13 years, Ultragenyx Pharmaceutical's highest PB Ratio was 382.95. The lowest was 2.87. And the median was 6.46.

RARE's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.8
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Ultragenyx Pharmaceutical's average Book Value Per Share Growth Rate was -256.30% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Ultragenyx Pharmaceutical was 25.80% per year. The lowest was -42.10% per year. And the median was -2.45% per year.

Back to Basics: PB Ratio


Ultragenyx Pharmaceutical  (NAS:RARE) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Ultragenyx Pharmaceutical PB Ratio Related Terms


Ultragenyx Pharmaceutical PB Ratio Historical Data

* Premium members only.

The historical data trend for Ultragenyx Pharmaceutical's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ultragenyx Pharmaceutical PB Ratio Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.32 9.23 14.29 15.26 0.00

Ultragenyx Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.57 23.16 316.63 0.00 0.00

RARE vs ELVN, KOD, CLDX: PB Ratio Comparison

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultragenyx Pharmaceutical PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's PB Ratio distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's PB Ratio falls into.


RARE
65GF Score
Ultragenyx Pharmaceutical Inc RARE
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ultragenyx Pharmaceutical PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Ultragenyx Pharmaceutical's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=29.25/-2.4
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Is Ultragenyx Pharmaceutical (RARE) Overvalued in 2026?

Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued. The current stock price of $29.25 is trading 37.8% below its estimated GF Value™ of $46.99. GuruFocus considers Ultragenyx Pharmaceutical to be Possible Value Trap.

Key valuation signals for RARE:

  • PB Ratio:
  • GF Value™: $46.99 vs. price of $29.25 (37.8% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the RARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ultragenyx Pharmaceutical Business Description

Address 60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
65GF Score

Get the complete analysis for RARE

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.25
Price
$46.99
GF Value